DEA Approves New Exempt Chemical Mixtures
Published Date: 5/20/2026
Notice
Summary
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
Certain lab mixtures exempted from parts of CSA
DEA approved specific chemical preparations listed in Chart I (applications received July 1, 2025 through March 31, 2026) as exempt from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the Controlled Substances Act and from 21 CFR 1301.74, effective as of the dates in the approval letters. The exemptions apply only to the exact preparations and forms described in the applications.
Some applications denied — products remain regulated
DEA determined that the chemical preparations listed in Chart II (applications received July 1, 2025 through March 31, 2026) are not exempt, so those specific products remain subject to all parts of the Controlled Substances Act and related regulations as of the dates in the determination letters. Companies listed in Chart II must comply with CSA and CFR requirements for those products.
Bulk-exempt products limited to in-house use
For exempted bulk products listed in this order, DEA determined they may only be used in-house by the manufacturer and may not be distributed for any purpose or transported to other facilities. This restriction is intended to limit diversion from larger bulk quantities.
Exemptions limited to exact formulation — changes need refile
The exemptions apply only to the precise composition, form, and trade name described in each application; any change in quantitative or qualitative composition or in the trade name after the application date requires a new application under 21 CFR 1308.24(h).
Other CSA requirements still apply (importer registration)
DEA states that the exemptions are limited to the specific CSA/CFR sections identified in 21 CFR 1308.24(a); all other CSA and CFR requirements remain in force, including registration as an importer as required by 21 U.S.C. 957. Affected entities must still meet those other obligations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four new substances—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these chemicals, including researchers and businesses, who must follow strict rules or face serious penalties. The move aims to keep communities safer by cracking down on these risky drugs.
Previous / Next Documents
Previous: 2026-10089 — Importer of Controlled Substances Application: Amneal Pharmaceuticals, LLC
Amneal Pharmaceuticals wants to become an official importer of a strong painkiller called Remifentanil. This means they’ll be allowed to bring this controlled drug into the U.S. People who make or use these drugs can share their thoughts or ask for a hearing by June 22, 2026. No direct money changes yet, but this move could affect drug availability and business in the future.
Next: 2026-10091 — Commission Information Collection Activities (FERC-919); Comment Request; Extension
FERC is extending its current info collection rules for another three years without any changes. This affects public utilities that sell electricity at market-based rates, making sure their prices stay fair. If you want to share your thoughts, you’ve got until July 20, 2026, to comment—no extra costs or new paperwork coming your way!